ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis third quarter 2025 financial results conference call |
| When: | Tuesday, November 11, 2025, at 4:30 p.m. ET (1:30 p.m. PT) |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 4402192. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. |
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.85 |
| Daily Change: | 0.06 2.15 |
| Daily Volume: | 1,113,157 |
| Market Cap: | US$259.550M |
November 11, 2025 November 10, 2025 October 15, 2025 October 13, 2025 September 02, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
